N-tert-Butyl-2-cyano-pyrrolidin | 62842-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-tert-Butyl-2-cyano-pyrrolidin
• 英文别名: 1-Tert-butylpyrrolidine-2-carbonitrile
• CAS: 62842-46-0
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: DTVOLMIFTHJEML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• CATECHOL-BASED DERIVATIVES FOR TREATING OR PREVENTING DIABETICS
  申请人：Kuo Yueh-Hsiung

  公开号：US20090143397A1

  公开（公告）日：2009-06-04

  The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetics and ischemics, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier.

  本发明提供了一种基于邻苯二酚的衍生物及其药用可接受的盐和溶剂化合物。一种用于预防或治疗糖尿病和缺血症的药物组合物，包括具有化学式(I)的基于邻苯二酚的衍生物和来自药用辅料、稀释剂和载体中选择的至少一种成分。
• NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF
  申请人：Khamar Bakulesh Mafatlal

  公开号：US20130137852A1

  公开（公告）日：2013-05-30

  The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below: Formula VI. Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptidase-IV enzyme is involved, such as diabetes and particularly type-2 diabetes.

  本发明涉及一种制备新化合物的方法，该化合物作为二肽基肽酶-IV酶的抑制剂，并由以下结构式VI所示：该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病和特别是2型糖尿病方面具有用处。
• Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：US10329282B2

  公开（公告）日：2019-06-25

  The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

  本发明涉及一种式（I）的Rho相关蛋白激酶抑制剂、一种包含其的药物组合物、其制备方法以及其用于预防或治疗由Rho相关蛋白激酶（ROCK）介导的疾病的用途。
• Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
  申请人：Hyundai Pharm Co., Ltd.

  公开号：US10723699B2

  公开（公告）日：2020-07-28

  The present invention relates to a cyclohexene derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating metabolic disease containing the cyclohexene derivative as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

  本发明涉及一种环己烯衍生物、其制备方法以及一种含有该环己烯衍生物作为活性成分的预防或治疗代谢性疾病的药物组合物。根据本发明的环己烯衍生物通过激活 G 蛋白偶联受体 119（GPR-119）来增加细胞内环磷酸腺苷（cAMP）的活性，同时通过诱导胰高血糖素样肽-1（GLP-1）的释放来表现出减肥和降血糖的效果、GLP-1 是一种神经内分泌蛋白，因此可作为药物组合物用于预防或治疗代谢性疾病，如肥胖、1 型糖尿病、2 型糖尿病、糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和 X 综合征。
• 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS
  申请人：Mission Therapeutics Limited

  公开号：EP3433246A1

  公开（公告）日：2019-01-30